Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Breast Neoplasms 15Prostatic Neoplasms 11Osteoporosis 6Neoplasms 4Melanoma 3Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Cardiovascular Diseases 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Unspecified Childhood Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Sarcoma, Ewing 1Regional Osteoporosis as a Result of Chemotherapy 1Recurrence 1Primary Ovarian Insufficiency 1Polycystic Ovary Syndrome 1Paraganglioma, Extra-Adrenal 1Pain 1Ovarian Neoplasms 1Osteosarcoma 1Oropharyngeal Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

lenvatinib 2Temozolomide 2temsirolimus 1penpulimab 1pazopanib 1cabozantinib 1anlotinib 1Vorinostat 1Vinorelbine 1Sirolimus 1Restraint, Physical 1Everolimus 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma, Extra-Adrenal × Absorptiometry, Photon × Clear all
NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

M.D. Anderson Cancer Center

Phase NA Completed
23 enrolled
CNSEndocrine

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡